CEO Adam Simon demonstrates the Borealis headset prototype.

Our product philosophy is to provide easy-to-use, portable, turn-key solutions to aid in the diagnosis and management of brain disorders. Cerora is building a novel healthcare platform to integrate collections of small biosensors to provide a multimodal signature of brain health.

Cerora Borealis™ (Possibly available 2021)

The Cerora Borealis medical device platform is subject to FDA review and designed to measure and record brainwave activity (EEG) as well as other biosensor data, including cognitive data and voice-based data streams. The platform provides state of the art, mobile and versatile multimodal biosensor data. The first release is intended as an adjunct to standard clinical practice to aid in the evaluation of subject’s medical or psychological state. Cerora’s next generation devices are intended to aid in the diagnosis and management of various brain disorders, injuries, and diseases.

The first release of Borealis is estimated to ship into US markets in 2021 at the earliest.